PIHTI ÖNLEYİCİ TEDAVİ: HEMŞİRELİK YAKLAŞIMLARI

Öz ÖZETPıhtılaşma; koroner arter hastalığı, serebrovasküler hastalık ve periferal arter hastalığı gibi iskemik hastalıklara neden olmaktadır. Bu hastalıkların önlenmesinde ve/veya tekrarlamamasında pıhtı önleyici tedavi vazgeçilmezdir. Tedavi kapsamında antiagregan, antikoagülan ve antitrombolitik ilaçlar kullanılmaktadır. Pıhtı önleyici tedavilerin kanama başta olmak üzere birçok yan etkisi bulunmaktadır. Verilen eğitim ile pıhtı önleyici tedavi alan hastaların tedaviye yönelik bilgi düzeyleri arttırılır, gelişebilecek komplikasyonlar önlenebilir ve hastanın hastalığını yönetebilmesi sağlanabilir. Bu nedenle, pıhtı önleyici tedavi alan hastaların tedavi süreçlerinde ve hasta/aile eğitiminde, hemşirelere önemli görevler düşmektedir. Anahtar kelimeler: Antikoagülan; antiagregan; hemşirelik; hasta eğitimi ABSTRACTAnticoagulant Therapy: Nursing Approaches Coagulation causes ischemic diseases like coronary artery disease, cerebrovascular disease, and peripheral arterial disease. Anticoagulant therapy is essential in the prevention and/or non-recurrence of these diseases. Antiaggregant, anticoagulant, and antithrombotic drugs are used within the scope of therapy. Anticoagulant therapies have a number of side effects primarily like bleeding. The trainings could increase the therapy-related knowledge of patients undergoing the anticoagulant therapy, prevent the possible complications, and enable patients to manage the disease. Therefore, nurses have important roles in the treatment process of patients undergoing the anticoagulant therapy and the patient/family education.  Keywords: Anticoagulant; antiaggregant; nursing; patient education

___

  • Abacı O, Kılıçkesmez KO. Aspirin Resistance: Where Are We Now? Anadolu Kardiyol Derg 2013; 13(4): 370-3.
  • Acar A, Hasbahçeci M, BaGak F, Canbak T, ÇalıGkan M, Alimoğlu O. Warfarin Doz Aşımına Bağlı Oluşan Kanamalar. Dicle Tıp Dergisi 2012;39(2):223-6.
  • AlıGır MF, KeçebaG M, BeGli F, ÇalıGkan S, Güngören F, Yıldırım A, ve ark. Varfarin Kullanan Hastalarda Etkin INR Düzeyi Oranları ve Etiyoloji ile Olan İlişkisi. Turkiye Klinikleri J Med Sci 2013;33(3):868-73
  • Alpay N, OkumuG G, Kıyan E, Diz-Küçükkaya R, Tabak L, Ece T, ve ark. Fondaparinuxla Tedavi Edilen Heparine Bağlı Trombositopeni Olgusu. Turk Toraks Der 2009;10(4): 193-5.
  • Alshbool FZ, Karim ZA, Vemana HP, Conlon C, Lin OA, Khasawneh FT. The Regulator of G-Protein Signaling 18 Regulates Platelet Aggregation, Hemostasis and Thrombosis. Biochem Biophys Res Commun 2015; 10;462(4): 378-82.
  • Andersson T, Nagy P, Niazi M, Nylander S, Galbraith H, Ranjan S, et al. Effect of Esomeprazole with/without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers. Am J Cardiovasc Drugs 2014; DOI 10.1007/s40256-014-0073-4
  • Biskupiak J, Ghate SR, Jiao T, Brixner D. Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation. J Manag Care Pharm 2013;19(9):789-98
  • Chiong JR, Cheung RJ. Long-Term Anticoagulation in the Extreme Elderly with the Newer Antithrombotics: Safe or Sorry? Korean Circ J 2013;43(5):287-92.
  • Davoren JB, Wang S. (Çev: Nizam İ.) Kan Hastalıkları. Hastalıkların Patofizyolojisi: Klinik Tıpla Bir Tanışma (Ed. McPhee SJ, Hammur GD) Palme Yayıncılık Ankara. 2012, p. 111-39
  • Doğan NÖ, Günaydın GP, Tekin M, Çevik Y. Nontraumatic Massive Spontaneous Hemothorax with Concomitant Warfarin Use. Case Reports in Emergency Medicine Volume 2013, Doi:10.1155/2013/546024
  • Dökmeci G, Dökmeci AH. Sağlık Bilimleri Fakültesi ve Sağlık Yüksekokulları için Farmakoloji, Kısaltılmış Temel Bilgiler. Nobel Tıp Kitabevi 2014, p:143-48
  • Ferreira Silva MV, SantAna Dusse LM, Vieira LM, Carvalho MG. Platelet Antiaggregants in Primary and Secondary Prevention of Atherothrombotic Events. Arq Bras Cardiol 2013;100(6):78-84.
  • Han ZH, Ren XJ, Wang Y. Anticoagulation Management of Patients with Long-Term Warfarin Therapy After Valve Replacement During the Perioperative Period of Pacemaker Implantation. Int J Clin Exp Med 2013;6(7):594-8
  • Isoda D, Kimura T, Nishimura K, Yamanaka N, Nakamura S, Ando M, et al. A Case Report of Pulmonary Thromboendarterectomy for Chronic Thromboembolism in a Patient with Protein C Deficiency. Ann Thorac Cardiovasc Surg 2014; doi: 10.5761/atcs.cr.13-00031.
  • Kayaalp SO. Akılcı Tedavi Yönünden Tıbbi Farmakoloji. Pelikan Yayıncılık 2012, p:509-36.
  • Kepez A, Erdoğan O. Anticoagulation for NonValvular Atrial Fibrillation: New Anticoagulant Agents. Anadolu Kardiyol Derg 2013; 13(4): 379-84
  • Kubesova HM, Weber P, Meluzinova H, Bielakova K, Matejovsky J. Benefits and Pitfalls of Cardiovascular Medication in Seniors. Wien Klin Wochenschr 2013; Doi 10.1007/s00508-013-0395-2
  • Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, et al. Impact of İnitial Clinical Presentation Onclopidogrel Low Response. Arch Cardiovasc Dis 2013;106(11): 593-600
  • Lip DY, Lane DA. Stroke Prevention with Oral Anticoagulation Therapy in Patients with Atrial Fibrillation, Focus on the Elderly. Circ J 2013; 77(6)1380-8
  • Maina MW, Pastakia SD, Manji L, Kirui N, Kirwa C, Karwa R. Describing the Profile of Patients on Concurrent Rifampin and Warfarin Therapy in Western Kenya: A Case Series. Drugs R D 2013; Doi: 10.1007/s40268-013-0023-7
  • Marcason W. Vitamin K: What Are the Current Dietary Recommendations for Patients Taking Coumadin? J Am Diet Assoc 2007;107(11):2022. Mete O. Besin uzmanı. Türkiye İş Bankası Kültür Yayınları 2012, s: 26-7
  • Meves SH, Hummel T, Endres HG, Maybo¨ck N, Kaiser AFC, Schro¨der KD et al. Effectiveness of Antiplatelet Therapy in Atherosclerotic Disease: Comparing the ASA Low-Response Prevalence in CVD, CAD and PAD. J Thromb Thrombolysis 2014; Doi:10.1007/s11239-013-0919-7
  • Mizia-Stec K, Haberka M, Mizia M, Lasota B, Kunecki M, Gieszczyk K, et al. Effects of Pantoprazole on Dual Antiplatelet Therapy in Stable Angina Pectoris Patients After Percutaneous Coronary İntervention. Pharmacological Reports 2012;64(2), 360-8
  • Njovane XW, Fasınu PSS, Rosenkranz B. Comparative Evaluation of Warfarin Utilisation in Two Primary Healthcare Clinics in the Cape Town Area. Cardiovasc J Afr 2013; 24(2): 19-23
  • Nural MS, Baydın A, KarataG AD, Elmalı M. Yüksek Doz Warfarin Kullanımı Sonucu Gelişen Yaygın Alveoler Hemoraji. Toraks Dergisi 2006; 7(1): 68-71
  • Pamukçu B, Oflaz H, Onur I, Cimen A, Nisanci Y. Effect of Cigarette Smoking on Platelet Aggregation. Clin Appl Thromb Hemost 2011;17(6):175-80.
  • Park IC, Baek YH, Han SY, Lee SW, Chung WT, Lee SW, et al. Simultaneous İntrahepatic and Subgaleal Hemorrhage in Antiphospholipid Syndrome Following Anticoagulation Therapy. World J Gastroenterol 2013;19(38): 6494-9
  • Qui JX, Zhou ZW, He ZX, Zhang X, Zhou SF, Zhu S. Estimation of the Binding Modes with İmportant Human Cytochrome P450 Enzymes, Drug İnteraction Potential, Pharmacokinetics, and Hepatotoxicity of Ginger Components Using Molecular Docking, Computational, and Pharmacokinetic Modeling Studies. Drug Design, Development and Therapy 2015;Doi: 10.2147/DDDT.S74669
  • Sağ C, Cansel M, Küçük T. Gebelik ve Warfarin Kullanımı. MN Kardiyoloji 2006;13(6): 377-80 Sencer E, Orhan Y. Beslenme. İstanbul Medikal Yayıncılık 2005, p. 217-22
  • Senchemkov A, Lemaine V, Tran NV. Management of Perioperative Microvascular Thrombotic Complications- The Use of Multiagent Anticoagulation Algorithm in 395 Consecutive Free Flaps. J Plast Reconstr Aesthet Surg 2015;68(9):1293- 303.
  • Shoeb M, Fong MC. Assessing Bleeding Risk in Patients Taking Anticoagulants. J Thromb Thrombolysis 2013; Doi: 10.1007/s11239-013-0899- 7
  • Soysal T. Antikoagülan Tedavi İlkeleri. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitim Etkinlikleri. Kanama ve Tromboza Eğilim Sempozyum Dizisi No:36, 2003; p. 159-74
  • Şendir M. Antikoagülan tedavi uygulanan nöroşirurji hastalarında bakım. İ.Ü.F.N. Hem. Derg 2008; 16(62):129-35.
  • TARDIS Trial Investigators, Krishnan K, Beridze M, Christensen H, Dineen R, Duley L, et al. Safety and Efficacy of İntensive vs. Guideline Antiplatelet Therapy in High-Risk Patients with Recent İschemic Stroke or Transient İschemic Attack: Rationale and Design of The Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke Trial. Int J Stroke 2015;10(7):1159-65.
  • Tayar M, HaGıl Korkmaz N, ÖzkeleG HE. Beslenme İlkeleri. Dora Basın Yayın 2011, p. 106-8
  • Tekinarslan G, Güler Ss, Utku U. Spontan İntraserebral Hemoraji: Etyoloji ve Bir Yıllık Prognozu Etkileyen Faktörler. Türk Nöroloji Dergisi 2012; Doi: 10.4274/Tnd.45220
  • Turfan M, Tasal A, Ergun F, Ergelen M. Tribulus Terrestris, Avena Sativa ve Panax Ginseng Kombinasyonu. Türk Kardiyol Dern Arş 2012;40(3):259-61.
  • Türk Hematoloji Derneği, Edinsel Kanama Bozuklukları ve Kalıtsal Trombofili Tanı ve Tedavi Kılavuzu 2011;5:82
  • Türk Kardiyoloji Derneği, Atriyal Fibrilasyon Tedavisi ESC Kılavuzunun 2012 Odaklı Güncellemesi 2013;3:53-81
  • Türk Toraks Derneği Pulmoner Embolizm Tanı Ve Tedavi Uzlaşı Raporu, 2009; 10(11):1-47
  • Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S. Guidelines for the Management of Anticoagulant and Antiplatelet Therapy in Patients Undergoing Endoscopic Procedures. Gut 2008; doi:10.1136/gut.2007.142497
  • Wahlqvist ML, Tanaka K, Tzeng BH. Clinical Decision-Making for Vitamin K-1 and K-2 Deficiency and Coronary Artery Calcification with Warfarin Therapy: Are Diet, Factor Xa İnhibitors or Both the Answer? Asia Pac J Clin Nutr 2013;22 (3):492-6.
  • Wang ZQ, Zhang R, Zhang PP, Liu XH, Sun J, Wang J, et al. Pharmacogenetics-Based Warfarin Dosing Algorithm Decreases Time to Stable Anticoagulation and the Risk of Major Hemorrhage: an Updated Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol 2015;65(4):364-70.
  • Yang SH, Yu CL, Chen HY, Lin YH. A Commonly Used Chinese Herbal Formula, Shu-Jing-Hwo-ShieeTang, Potentiates Anticoagulant Activity of Warfarin in A Rabbit Model. Molecules 2013; doi:10.3390/molecules18101171.